Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹1841.76 Cr |
| Fresh Issue | ₹760.52 Cr |
| Offer for Sale | ₹1081.24 Cr |
| Face Value | ₹2 Per Equity Share |
| Price Band | ₹430.00-452.00 per share |
| Discount | Retail: 0.00,Employee: 30.00 |
| BSE Code | 544172 |
| NSE Code | INDGN |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Kotak Mahindra Capital Co.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 33 shares and in multiples thereof
Founded in 1998, Indegene Limited provides digital services for the life sciences industry. They assist with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales/marketing support.
The company's services can be divided into following categories
The subsidiary of the company, DT Associates Limited, provides consulting services under the "DT Consulting" brand. It helps life sciences companies manage their digital transformation efforts to ensure continued success in customer experience.
The company received the Platinum Level award at the 2023 Healthy Workplace Conference and Awards, a recognition given by Arogya World India Trust in partnership with the Public Health Foundation of India.
As of December 31, 2023, the company had 65 clients actively engaged with its services.
As of December 31, 2023, the company employed 5,181 people worldwide. Of these, 4,461 are based in India, 530 work in North America, 105 in Europe, 73 in China, and 12 in other regions.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/prepaymentof indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc | 391.34 |
| 2 | Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc. | 102.92 |
| 3 | General Corporate Purposes and Inorganic Growth | 230.12 |
| Period Ended | 31 Dec 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 2,518.15 | 2,203.87 | 1,353.47 | 596.04 |
| Total Income | 1,969.75 | 2,364.10 | 1,690.50 | 996.92 |
| Profit After Tax | 241.90 | 266.10 | 162.82 | 149.41 |
| NET Worth | 1,327.00 | 1,063.72 | 763.90 | 324.51 |
| Reserves and Surplus | 1,282.65 | 1,019.43 | 763.55 | 324.19 |
| Total Borrowing | 399.33 | 394.34 | 18.24 | 24.76 |
| Amount in ₹ Crore | ||||
| KPI | Dec 31, 2023 |
|---|---|
| Debt / Equity | 0.30% |
| RoNW | 18.23% |
| PAT Margin | 12.62% |
| Price to Book Value | 7.55 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 11.96 | 13.48 |
| P/E (x) | 37.78 | 33.53 |
| Promoter Holding | 30.71% | 26.76% |
| Market Cap | ₹10814.07 Cr. | |
